Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series
Source : https://www.frontiersin.org/articles/10.3389/fonc.2022.901797/full
BackgroundRelapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL) is an intractable situation without sound treatment. Bruton's tyrosine kinase (BTK) represents an attractive drug target in PCNSL. Orelabrutinib is a new-generation...
Conclusion: Orelabrutinib-containing regimen was effective and well-tolerated in patients with r/r PCNSL. Genome sequencing of tumor samples could help to screen patients who may respond to the orelabrutinib-containing regimen, and liquid biopsy may contribute to tracing tumor burden and monitoring treatment response.
Regulatory programs of B-cell activation and germinal center reaction allow B-ALL escape from CD19 CAR T-cell therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35759797/
Chimeric-antigen receptor (CAR) T-cell therapy has led to tremendous successes in the treatment of B-cell malignancies. However, a large fraction of treated patients relapse, often with disease expressing reduced levels...
Conclusion/Relevance: These results demonstrate transcriptional plasticity as an underlying mechanism of escape from CAR T cells and highlight the importance of combining CAR T-cell therapy with targeted therapies that aim to overcome this plasticity.
Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases
Source : https://www.sciencedirect.com/science/article/abs/pii/S0223523422004536?via=ihub
JAK-based dual inhibitors have increasingly emerged last twenty years. * Developments or discoveries of JAK-based dual inhibitors are summarized. * JAK-based dual inhibitors manifest superiority over single kinase inhibitors. *...
Conclusion/Relevance: In this review, we elucidated the possible mechanism of synergic effects caused by dual JAK inhibitors and briefly describe the development of these agents.
Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35757723/
doi: 10.3389/fimmu.2022.894787. 1 Department of Hematology, Shaoxing Second Hospital, Shaoxing, China. 2 Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Free PMC article Free...
Conclusion: We report the first successful case of dual inhibition of HDAC and BTK for the treatment of R/R DLBCL after failure to CAR-T cell therapy, which opens a new therapeutic possibility for the future.
Investigating The Impact of Covalent and Non-covalent Binding Modes of Inhibitors on Bruton's Tyrosine Kinase in the Treatment of B Cell Malignancies-Computational Insights - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35718983/
Background Bruton tyrosine kinase plays a key role in the survival, proliferation, activation and differentiation of B-lineage cells and the signaling of other receptors. It is overexpressed and constitutively active...
Relevance: In this study we employed two new second generation inhibitors with different binding modes, Zanubrutinib and AS-1763, which are at various levels of clinical trials to highlight the molecular determinants in the therapeutic inhibition of BTK through computational studies.